Immunohistochemical staining of Ki-67 using the monoclonal antibody Ki-sll is a prognostic indicator for laryngeal squamous cell carcinoma

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1459-1466

  Cordes, Christian ^a,b   Münzel, Ann Kristin ^a   Rudolph, Pierre ^b   Hoffmann, Markus ^a   Ivo, Leuschner ^b   Gottschlich, Stefan ^a  

^a Department of Otolaryngology Head and Neck Surgery   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Ki 67; Ki sl 1; Laryngeal cancer; Squamous cell carcinoma

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROL GROUP; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ACTIVITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LARYNGEAL NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 64949173438     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. DeRienzo DP, Greenberg SD and Fraire AE: Carcinoma of the larynx. Changing incidence in women. Arch Otolaryngol Head Neck Surg 117: 681-684, 1991.
2. Ji WY, Du Q, Guan C and Wang DG: Survival analysis of 1,115 patients with laryngeal carcinoma. Zhonghua Er Bi Yan Hou Ke ZaZhi 39: 17-19,2004.
3. Almadori G, Bussu F and Paludettii G: Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification. Acta Otorhinolaryngol Ital 26: 326-34, 2006.
4. Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A and Burgues J: Second neoplasm in patients with head and neck cancer. Head Neck 21: 204-210, 1999.
5. Dequanter D and Lothaire P: The role of salvage surgery in organ preservation strategies in advanced head and neck cancer. B-ENT 4: 77-80, 2008.
6. Leon X, Lopez M, Garcia J, Viza I, Orus C and Quer M: Supracricoid laryngectomy as salvage surgery after failure of radiation therapy. Eur Arch Otorhinolaryngol 264: 809-814,2007.
7. Jones AS, Roland NJ, Caslin AW, Cooke TG, Cooke LD and Forster G: A comparison of cellular proliferation markers in squamous cell carcinoma of the head and neck. J Laryngol Otol 108: 859-864, 1994.
8. Roland NJ, Caslin AW, Bowie GL and Jones AS: Has the cellular proliferation marker Ki-67 any clinical relevance in squamous cell carcinoma of the head and neck? Clin Otolaryngol 19: 13-18, 1994.
9. Theegarten D, Barfuss A, Gellrich NC and Philippou S: Expression of proliferation markers PCNA and MIB1 in verrucous squamous epithelial carcinoma of the oral cavity. Mund Kiefer Gesichtschir 1: 133-136, 1997.
10. Patel SG and Shah JP: TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 55: 242-58, 2005.
11. Kearsley JH, Furlong KL, Cooke RA and Waters MJ: An immunohistochemical assessment of cellular proliferation arkers in head and neck squamous cell cancers. Br J Cancer 1: 821-827, 1990.
12. Roland NJ, Caslin AW, Nash J and Stell PM: Value of grading quamous cell carcinoma of the head and neck. Head Neck 14: 224-229,1992.
13. Barbareschi M, Girlando S, Mauri FA, Arrigoni G, Laurino L, Dalla PP and Doglioni C: Tumour suppressor gene products, proliferation and differentiation markers in lung neuroendocrine neoplasms. J Pathol 166: 343-350, 1992.
14. Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, Thompson N and Lloyd RV: Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 6: 663-668, 1993.
15. Kuropkat C, Rudolph P, Frahm SO, Parwaresch R and Werner JA: Proliferation marker Ki-Sl 1-a prognostic indicator for squamous cell carcinoma of the hypopharynx. Virchows Arch 435: 590-595, 1999.
16. Kreipe H and Parwaresch R: A closer look at the cell cycle. Virchows Arch A Pathol Anat Histopathol 422: 341-343, 1993.
17. Rudolph P, Kellner U, Chassevent A, Collin F, Bonichon F, Parwaresch R and Coindre JM: Prognostic relevance of a novel proliferation marker, Ki-Sl 1, for soft-tissue sarcoma. A multivariate study. Am J Pathol 150: 1997-2007, 1997.
18. Kohler G and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. J Immunol 174: 2453-2455,2005.
19. Kellner U, Heidebrecht HJ, Rudolph P, Biersack H, Buck F, Dakowski T, Wacker HH, Domanowski M, Seidel A, Westergaard O and Parwaresch R: Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies. J Histochem Cytochem 45: 251-263,1997.
20. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
21. Jung SH and Jeong JH: Rank tests for clustered survival data. Lifetime Data Anal 9: 21-33, 2003.
22. Ambrosch P: The role of laser microsurgery in the treatment of laryngeal cancer. Curr Opin Otolaryngol Head Neck Surg 15: 82-88,2007.
23. Swoboda H and Denk DM: Diagnosis and therapy of laryngeal carcinoma. Radiologe 38: 83-92, 1998.
24. Dreyfuss AI and Clark JR: Analysis of prognostic factors in squamous cell carcinomas of the head and neck. Hematol Oncol Clin North Am 5: 701-712, 1991.
25. Janot F, Klijanienko J, Russo A, Mamet JP, de Braud F, El Naggar AK, Pignon JP, Luboinski B and Cvitkovic E: Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer 73: 531-538, 1996.
26. Berrino F and Gatta G: Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. EUROCARE Working Group. Eur J Cancer 34: 2154-2161, 1998.
27. Cardoso WP, Denardin OV, Rapoport A, Araujo VC and Carvalho MB: Proliferating cell nuclear antigen expression in mucoepidermoid carcinoma of salivary glands. Sao Paulo Med J 118: 69-74,2000.
28. Reitmaier M, Rudlowski C, Biesterfeld S, Rath W and Schroder W: Comparative studies on the biological significance of the marker for proliferation Ki-67 antigen and PCNA in primary ovarian carcinoma. Zentralbl Gynakol 122: 361-367, 2000.
29. Cappiello J, Nicolai P, Antonelli AR, Facchetti F, Cadei M, Cornacchiari A and Grigolato PG: DNA index, cellular proliferative activity and nucleolar organizer regions in cancers of the larynx. Eur Arch Otorhinolaryngol 252: 353-358, 1995.
30. Kotelnikov V, Cass L, Coon JS, Spaulding D and Preisler HD: Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues. Clin Cancer Res 3: 669-673, 1997.
31. Quinn CM and Wright NA: The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 160: 93-102, 1990.
32. Pich A, Chiusa L and Navone R: Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 15: 1319-1329, 2004.
33. Rudolph P, Lappe T, Schubert C, Schmidt D, Parwaresch RM and Christophers E: Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol 147: 1615-1625, 1995.
34. Kreipe H, Heidebrecht HJ, Hansen S, Rohlk W, Kubbies M, Wacker HH, Tiemann M, Radzun HJ and Parwaresch R: A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-Sl. Am J Pathol 142: 3-9, 1993.
35. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873, 1991.
36. Heidebrecht HJ, Buck F, Haas K, Wacker HH and Parwaresch R: Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the "Ki-67" proteins. Cell Prolif 29: 413-425, 1996.
37. Ahmed WA, Suzuki K, Imaeda Y and Horibe Y: Ki-67, p53 and epidermal growth factor receptor expression in early glottic cancer involving the anterior commissure treated with radiotherapy. Auris Nasus Larynx 35: 213-219, 2008.
38. Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW and Suthipintawong C: Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol 115: 709-718, 2001.
39. Gerdes J, Lelle RJ, Pickartz H, Heidenreich W, Schwarting R, Kurtsiefer L, Stauch G and Stein H: Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 39: 977-980, 1986.
40. Gerdes J, Dallenbach F, Lennert K, Lemke H and Stein H: Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki - 67. Hematol Oncol 2: 365-371, 1984.
41. Porschen R, Lohe B, Hengels KJ and Borchard F: Assessment of cell proliferation in colorectal carcinomas using the monoclonal antibody Ki-67. Correlation with pathohistologic criteria and influence of irradiation. Cancer 64: 2501-2505, 1989.
42. Pugsley JM, Schmidt RA and Vesselle H: The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer J 8: 222-233, 2002.
43. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
44. Rudolph P, Bonichon F, Gloeckner K, Collin F, Chassevent A, Schmidt D, Coindre JM, Parwaresch R and Kloppel G: Comparative analysis of prognostic indicators for sarcomas of the soft parts and the viscerae. Verh Dtsch Ges Pathol 82: 246-52, 1998.
45. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P and Grenman R: Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol 117: 312-315, 1997.
46. Hagedorn HG, Tubel J, Wiest I and Nerlich AG: In situ apoptotic and proliferation index in laryngeal squamous cell carcinomas. Anal Cell Pathol 16: 177-184, 1998.
47. Welkoborsky HJ, Hinni M, Dienes HP and Mann WJ: Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumour front grading and proliferation markers. Ann Otol Rhinol Laryngol 104: 503-510, 1995.
48. Steinhart H, Schroeder HG, Buchta B, Schmidt A and Kleinsasser O: Prognostic significance of extra-capsular invasion in cervical lymph node metastases of squamous epithelial carcinoma. Laryngorhinootologie 73: 620-625, 1994.